natgillin/translations-raw huggingface dataset:
Elderly There is no experience with the use of Yargesa in patients over the age of 70. 
Nema iskustava s primjenom lijeka Yargesa u bolesnika starijih od 70 godina.
The capsules are presented in a PVC and polychlorotrifluoroethylene (PCTFE) blister sealed with aluminium foil. 
Kapsule se nalaze u blisteru od PVC-a i poliklorotrifluoroetilena (PCTFE) koji je zatvoren aluminijskom folijom.
What you need to know before you take Yargesa 
Što morate znati prije nego počnete uzimati lijek Yargesa
Cases of peripheral neuropathy have been reported in patients treated with miglustat with or without concurrent conditions such as vitamin B12 deficiency and monoclonal gammopathy. 
Kod bolesnika liječenih miglustatom zabilježeni su slučajevi periferne neuropatije prisutne bez ili sa popratnim stanjima kao što su nedostatak vitamina B12 i monoklonalna gamapatija.
Use of Yargesa in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2) is not recommended. 
Primjena lijeka Yargesa kod bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min/1,73 m2) se ne preporučuje.
Growth should be monitored in paediatric and adolescent patients during treatment with Yargesa; the benefit/risk balance should be re-assessed on an individual basis for continuation of therapy. 
U tijeku liječenja Yargesa treba pratiti rast pedijatrijskih bolesnika i adolescenata; omjer koristi/rizika treba ponovo individualno procjenjivati za nastavak liječenja.
Very common effects - may affect more than 1 in 10 people The most common side effects are diarrhoea, flatulence (wind), abdominal (stomach) pain, weight loss and decreased appetite. 
Vrlo česte nuspojave - mogu se javiti u više od 1 na 10 osoba Najčešće nuspojave su proljev, flatulencija (vjetrovi), bol u trbuhu, gubitak težine i smanjen tek.
Yargesa should not be taken during breast-feeding. 
Lijek Yargesa ne smije se uzimati tijekom dojenja.
Overall the data show that treatment with Yargesa can reduce the progression of clinically relevant neurological symptoms in patients with Niemann-Pick type C disease. 
Ukupni podatci pokazuju da liječenje Yargesa može smanjiti progresiju klinički relevantnih neuroloških simptoma u bolesnika s Niemann-Pickove bolesti tipa C.
• For Niemann-Pick type C disease: For adults and adolescents (over 12 years old), the usual dose is two capsules (200 mg) three times a day (morning, afternoon and evening). 
• Za Niemann-Pickovu bolest tipa C: za odrasle i adolescente (starije od 12 godina) uobičajena doza su dvije kapsule (200 mg) tri puta dnevno (ujutro, popodne i navečer).
This study was conducted over a 6-month randomised comparison period followed by 18 months extension where all patients received miglustat monotherapy. 
To je ispitivanje provedeno u 6-mjesečnom randomiziranom komparativnom razdoblju nakon čega je slijedilo 18 mjesečni nastavak u kojem su svi bolesnici primali monoterapiju miglustatom.
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
OSTALI UVJETI I ZAHTJEVI ZA STAVLJANJE LIJEKA U PROMET
In patients included in the clinical trial, 40%-50% of patients had platelet counts below the lower limit of normal at baseline. 
Kod bolesnika uključenih u kliničko ispitivanje, 40% - 50% bolesnika broj trombocita na početku bio je ispod donje granice normale.
Other possible side effects are muscular spasms or weakness, fatigue, chills and malaise, depression, difficulty sleeping, forgetfulness and reduced libido. 
Ostale moguće nuspojave su grčevi u mišićima ili slabost, umor, zimica i malaksalost, depresija, poteškoće sa spavanjem, zaboravljivost i smanjen libido.
Use in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2) is not recommended (see sections 4.4 and 5.2). 
Primjena kod bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min/1,73 m2) se ne preporučuje (vidjeti dijelove 4.4 i 5.2).
Peripheral neuropathy, ataxia, amnesia, paraesthesia, hypoaesthesia, headache, dizziness 
Periferna neuropatija, ataksija, amnezija, parestezija, hipoestezija, glavobolja, omaglica
In vitro, glucosylceramide synthase is inhibited by miglustat with an IC50 of 20-37 µM. 
In vitro, miglustat inhibira glukozilceramid sintazu s IC50 koji iznosi 20 37 µM.
Pharmacokinetic parameters of miglustat were assessed in healthy subjects, in a small number of patients with type 1 Gaucher disease, Fabry disease, HIV-infected patients, and in adults, adolescents and children with Niemann-Pick type C disease or type 3 Gaucher disease. 
Farmakokinetički parametri miglustata ocjenjivani su u zdravih osoba, kod malog broja bolesnika s Gaucherovom bolesti tipa 1, Fabrijevom bolesti, kod bolesnika zaraženih HIV-om, te kod odraslih, adolescenata i djece s Niemann-Pickovom bolesti tipa C ili Gaucherovom bolesti tipa
Administration of miglustat to male and female CD1 mice by oral gavage at dose levels of 210, 420 and 840/500 mg/kg/day (dose reduction after half a year) for 2 years resulted in an increased incidence of inflammatory and hyperplastic lesions in the large intestine in both sexes. 
Primjena miglustata kod muških i ženskih CD1 miševa oralnom sondom tijekom 2 godine u dozama od 210, 420 i 840/500 mg/kg/dan (smanjenje doze nakon pola godine) za rezultat je imala povećanu incidenciju upalnih i hiperplastičnih lezija u debelom crijevu kod oba spola.
Miglustat affected embryo/foetal survival in rats and rabbits, dystocia was reported, postimplantation losses were increased, and an increased incidence of vascular anomalies occurred in rabbits. 
Miglustat djeluje na preživljavanje embrija/fetusa u štakora i kunića, primijećena je distocija, porasli su gubitci nakon implantacije i došlo je do povećane incidencije vaskularnih anomalija kod kunića.
The mechanism is most likely inhibition of intestinal disaccharidases such as sucrase-isomaltase in the gastrointestinal tract leading to reduced absorption of dietary disaccharides. 
Mehanizam je najvjerojatnije inhibicija intestinalnih disaharidaza kao što je sukraza-izomaltaza u probavnom traktu, što dovodi do smanjene apsorpcije disaharida iz hrane.
• Yargesa is also used to treat progressive neurological symptoms in Niemann-Pick type C disease in adults and in children. 
• Yargesa se također primjenjuje za liječenje progresivnih neuroloških simptoma kod Niemann-Pickove bolesti tipa C u odraslih i djece.
There is limited experience with the use of Yargesa in Niemann-Pick type C disease patients under the age of 4 years. 
Postoji ograničeno iskustvo u primjeni Yargesa kod bolesnika s Niemann-Pickovom bolesti tipa C, mlađih od 4 godine.
Capsule content sodium starch glycolate (Type A) povidone (K-29/32) magnesium stearate 
Sadržaj kapsule natrijev škroboglikolat (vrsta A), povidon (K-29/32), magnezijev stearat.
These findings were considered to be secondary to debilitation. 
Ovi se nalazi smatraju posljedicom slabljenja organizma.
Gaucher disease is an inherited metabolic disorder caused by a failure to degrade glucosylceramide resulting in lysosomal storage of this material and widespread pathology. 
Gaucherova bolest je nasljedni poremećaj metabolizma uzrokovan nemogućnošću razgradnje glukozilceramida, što za posljedicu ima pohranjivanje tog materijala u lizosomima i raširenu patologiju.
If you take more capsules than you were told to, consult your doctor immediately. 
Ako uzmete više lijeka Yargesa nego što ste trebali Smjesta se obratite svom liječniku ako ste uzeli više kapsula nego
Reduced growth has been reported in some paediatric patients with Niemann-Pick type C disease in the early phase of treatment with miglustat where the initial reduced weight gain may be accompanied or followed by reduced height gain. 
Kod nekih pedijatrijskih bolesnika s Niemann-Pickovom bolesti tipa C zabilježeno je smanjenje rasta u ranoj fazi liječenja miglustatom kada početno smanjeno dobivanje na težini može biti popraćeno smanjenjem rasta ili ono može uslijediti kasnije.
Peel back paper at arrows 
Odvojite pozadinski papir kod strelica
If any of these side effects cause problems, consult your doctor. 
Ako Vam bilo koja od tih nuspojava stvara poteškoće, obratite se Vašem liječniku.
Male patients should maintain reliable contraceptive methods while taking Yargesa. 
Muški bolesnici trebaju primjenjivati pouzdane metode kontracepcije dok uzimaju lijek Yargesa.
Pack size of 84 capsules. 
Veličina pakiranja: 84 kapsule.
The benefit of treatment with Yargesa for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be reappraised after at least 1 year of treatment with Yargesa. 
Korist od liječenja Yargesa kod neuroloških manifestacija u bolesnika s Niemann-Pickovom bolesti tipa C treba redovito ocjenjivati, npr. svakih 6 mjeseci; nastavak liječenja treba ponovo procijeniti nakon najmanje 1 godine liječenja Yargesa.
Several metabolites were identified in urine and faeces. 
U urinu i fecesu uočeno je nekoliko metabolita.
He or she may reduce the dose of Yargesa or recommend other medicines to help control side effects. 
Liječnik može smanjiti dozu lijeka Yargesa ili preporučiti drugi lijek koji bi pomogao držati pod nadzorom te nuspojave.
This leaflet was last revised in 
Ova uputa je zadnji put revidirana u <{MM/GGGG}> <{mjesec GGGG}>.
The benefit to the patient of treatment with Yargesa should be evaluated on a regular basis (see section 4.4). 
Potrebno je redovito procjenjivati korist za bolesnika od liječenja Yargesa (vidjeti dio 4.4).
If you stop taking Yargesa 
Ako prestanete uzimati lijek Yargesa
There was no drug-related increase in tumour incidence in any other organ. 
Nije bilo povećanja incidencije tumora povezanih s lijekom bilo kojeg drugog organa.
The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or a decrease in body weight, while taking Yargesa. 
Razlog za te pretrage je taj što što su neki bolesnici, dok su uzimali lijek Yargesa, osjećali trnce ili obamrlost u šakama i stopalima ili im se smanjila tjelesna težina.
The kinetics of miglustat appear to be dose linear and time independent. 
Pokazalo se da je kinetika miglustata ovisna o dozi a neovisna o vremenu.
Miglustat is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids. 
Miglustat je inhibitor glukozilceramid sintaze, enzima odgovornog za prvi korak u sintezi većine glikolipida.
Administration of miglustat to male and female Sprague-Dawley rats by oral gavage for 2 years at dose levels of 30, 60 and 180 mg/kg/day resulted in an increased incidence of testicular interstitial cell (Leydig cell) hyperplasia and adenomas in male rats at all dose levels. 
Primjena miglustata kod muških i ženskih Sprague-Dawley štakora oralnom sondom tijekom 2 godine u dozama od 30, 60 i 180 mg/kg/dan za rezultat je imala povećanu incidenciju hiperplazije testikularnih intersticijskih stanica (Leydigove stanice) i adenoma u muških štakora pri svim razinama doza.
INFORMATION IN BRAILLE Yargesa 100 mg 
Yargesa 100 mg
- If you have any further questions, ask your doctor or pharmacist. 
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
Do not take this medicine after the expiry date which is stated on the blister and carton after ‘EXP'. 
Ovaj lijek se ne smije upotrijebit nakon isteka roka valjanosti navedenog na kutiji iza oznake „Rok valjanosti“.
3 Push product through foil 
Gurnite lijek kroz foliju
The inhibitory action on glucosylceramide synthase forms the rationale for substrate reduction therapy in Gaucher disease. 
Inhibitorno djelovanje na glukozilceramid sintazu predstavlja logičku podlogu za liječenje smanjenjem supstrata kod Gaucherove bolesti.
A mean increase in haemoglobin concentration of 0.26 g/dl and a mean platelet count increase of 8.29 × 109/l were observed. 
Uočeno je prosječno povećanje koncentracije hemoglobina za 0,26 g/dl i prosječno povećanje broja trombocita za 8,29 × 109/l.
The usual dose of Yargesa in adult patients was 200 mg t.i.d., and was adjusted according to body surface area in paediatric patients. 
Uobičajena doza Yargesa u odraslih bolesnika bila je 200 mg triput dnevno, a kod pedijatrijskih bolesnika je bila prilagođena veličini površine tijela.
Weight loss, decreased appetite 
Gubitak težine, smanjen apetit Psihijatrijski poremećaji Često
29 patients continued in the extension period. 
Dvadeset i devet bolesnika nastavilo je s liječenjem u razdoblju nastavka.
If you forget to take Yargesa 
Ako ste zaboravili uzeti lijek Yargesa
Diarrhoea, flatulence, abdominal pain 
Proljev, flatulencija, bolovi u trbuhu
Printing ink shellac glaze iron oxide black (E172) propylene glycol concentrated ammonia solution 
Tinta za označavanje šelak glazura, željezov oksid, crni (E172) propilenglikol, koncentrirana otopina amonijaka.
Until further information is available, before seeking to conceive, male patients should cease Yargesa and maintain reliable contraceptive methods for a further 3 months. 
Do dostupnosti daljnjih informacija, prije pokušaja začetka djeteta, muški bolesnici trebaju prekinuti uzimanje lijeka Yargesa i primjenjivati pouzdane metode kontracepcije daljnja 3 mjeseca.
Each hard capsule contains 100 mg miglustat. 
Svaka tvrda kapsula sadrži 100 mg miglustata.
Studies in the rat have shown that miglustat adversely affects spermatogenesis and sperm parameters, and reduces fertility (see sections 4.6 and 5.3). 
Ispitivanja na štakorima pokazala su da miglustat štetno djeluje na spermatogenezu i parametre sperme, te da umanjuje plodnost (vidjeti dijelove 4.6 i 5.3).
The benefit of treatment with Yargesa for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be reappraised after at least 1 year of treatment with Yargesa, (see section 4.4). 
Korist od liječenja Yargesa kod neuroloških manifestacija u bolesnika s Niemann-Pickovom bolesti tipa C treba redovito ocjenjivati, npr. svakih 6 mjeseci; nastavak liječenja treba ponovo procijeniti nakon najmanje 1 godine liječenja Zavescom (vidjeti dio 4.4).
The pharmacokinetics of miglustat is similar in adult type 1 Gaucher disease patients and Niemann-Pick type C disease patients when compared to healthy subjects. 
Farmakokinetika miglustata slična je onoj u odraslih bolesnika s Gaucherovom bolesti tipa 1 i NiemannPickovom bolesti tipa C kada se usporedi sa zdravim osobama.
Weight loss has been reported in 55% of patients using miglustat. 
U 55 % bolesnika liječenih miglustatom zabilježen je gubitak tjelesne težine.
In patients with type 1 Gaucher disease, monitoring of platelet counts is recommended. 
Kod bolesnika s Gaucherovom bolesti tipa 1 preporučuje se praćenje broja trombocita.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 100 mg miglustat. 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tvrda kapsula sadržava 100 mg miglustata.
Studies in the rat have shown that miglustat adversely affects sperm parameters (motility and morphology) thereby reducing fertility (see sections 4.4 and 5.3). 
Ispitivanja na štakorima su pokazala da miglustat štetno djeluje na parametre sperme (motilitet i morfologiju) te umanjuje plodnost (vidjeti dijelove 4.4 i 5.3).
Yargesa works by inhibiting the enzyme called ‘glucosylceramide synthase' which is responsible for the first step in the synthesis of most glycosphingolipids. 
Yargesa djeluje kao inhibitor enzima 'glukozilceramid sintaze', odgovornog za prvi korak u sintezi većine glikosfingolipida.
Nausea, vomiting, abdominal distension/discomfort, constipation, dyspepsia Musculoskeletal and connective tissue disorders Common 
Mučnina, povraćanje, abdominalna distenzija/nelagoda, konstipacija, dispepsija Poremećaji mišićno-koštanog sustava i vezivnog tkiva Često
• Yargesa is used to treat mild to moderate type 1 Gaucher disease in adults. 
• Yargesa se primjenjuje za liječenje blage do umjerene Gaucherove bolesti tipa 1 u odraslih.
NAME OF THE MARKETING AUTHORISATION HOLDER Piramal Critical Care B.V. 
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Piramal Critical Care B.V.
Temporary dose reduction to 100 mg once or twice a day may be necessary in some patients because of diarrhoea. 
Kod nekih će bolesnika možda biti potrebno privremeno smanjenje doze na 100 mg jedanput ili dvaput dnevno, zbog proljeva.
Thrombocytopenia Metabolism and nutrition disorders Very common 
Poremećaji metabolizma i prehrane Vrlo često
Small mean reductions in haemoglobin [-0.95 g/dL (95% CI: -1.38, -0.53)] and platelet count [-44.1 × 109/L (95% CI: -57.6, -30.7)] were observed between baseline and end of study. 
Između početka i kraja ispitivanja uočeno je malo prosječno smanjenje hemoglobina [-0,95 g/dL (95% CI: -1,38; -0,53)] i broja trombocita [-44,1 × 109/L (95% CI: -57,6; -30,7)].
Miglustat has been administered at doses of up to 3000 mg/day for up to six months in HIV positive patients during clinical trials. 
Miglustat je u kliničkim ispitivanjima kod HIV pozitivnih bolesnika primjenjivan u dozama do 3 000 mg/dan tijekom najviše šest mjeseci.
Breast-feeding It is not known if miglustat is secreted in breast milk. 
Nije poznato izlučuje li se miglustat u majčino mlijeko.
Common side effects of treatment include headache, dizziness, paraesthesia (tingling or numbness), abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea (feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and thrombocytopenia (reduced levels of blood platelets).The neurological symptoms and thrombocytopenia could be due to the underlying disease. 
Česte nuspojave liječenja uključuju glavobolju, omaglicu, paresteziju (trnci ili obamrlost), poremećenu koordinaciju, hipoesteziju (oslabljen osjet na dodir), dispepsiju (žgaravica), mučninu, zatvor i povraćanje, oticanje ili nelagoda u abdomenu (trbuhu) i trombocitopeniju (smanjenje broja trombocita).
Adverse events observed included granulocytopenia, dizziness and paraesthesia. 
Primijećeni su štetni događaji koji uključuju granulocitopeniju, omaglicu i paresteziju.
INSTRUCTIONS ON USE 
15. UPUTE ZA UPOTREBU
Do not drive or use any tools or machines if you feel dizzy. 
Ako osjećate omaglicu, nemojte voziti niti raditi sa alatima i strojevima.
The apparent volume of distribution of miglustat is 83 l. Miglustat does not bind to plasma proteins. 
Prividni volumen distribucije miglustata je 83 l.
In 11 clinical trials in different indications 247 patients were treated with miglustat at dosages of 50-200 mg t.i.d. 
U 11 kliničkih ispitivanja s različitim indikacijama 247 bolesnika je liječeno Yargesa u dozama od 50-200 mg triput dnevno, u prosječnom trajanju od 2,1 godine.
Marketing Authorisation Holder and Manufacturer Piramal Critical Care B.V. 
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač: Piramal Critical Care B.V.
There was a mean increase of 22.2 × 109/l in platelet count, and a mean increase of 0.95 g/dl in haemoglobin concentration. 
Uočeno je prosječno povećanje broja trombocita od 22,2 × 109/l i prosječno povećanje koncentracije hemoglobina od 0,95 g/dl.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
U slučaju bilo kakvih pitanja u vezi s primjenom ovoga lijeka, obratite se liječniku ili ljekarniku.
Type 1 Gaucher disease 
Gaucherova bolest tipa 1
Until further information is available, it is advised that before seeking to conceive, male patients should cease Yargesa and maintain reliable contraceptive methods for 3 months thereafter. 
Do dostupnosti daljnjih informacija savjetuje se muškim bolesnicima da prije pokušaja začeća djeteta prekinu uzimanje lijeka Yargesa i primjenjuju pouzdane metode kontracepcije daljnja 3 mjeseca.
The recommended starting dose for the treatment of adult patients with Type 1 Gaucher disease is 100 mg three times a day. 
Preporučena početna doza za liječenje odraslih bolesnika s Gaucherovom bolesti tipa 1 je 100 mg triput dnevno.
The recommended dose for the treatment of adolescent patients (12 years of age and above) with NiemannPick type C disease is 200 mg three times a day. 
Preporučena doza za liječenje adolescentnih bolesnika (12 godina i starijih) s Niemann-Pickovom bolesti tipa C je 200 mg triput dnevno.
In patients with an adjusted creatinine clearance of 50-70 ml/min/1.73 m2, administration should commence at a dose of 100 mg twice daily in patients with type 1 Gaucher disease and at a dose of 200 mg twice daily (adjusted for body surface area in patients below the age of 12) in patients with Niemann-Pick type C disease. 
Kod bolesnika s prilagođenim klirensom kreatinina od 50-70 ml/min/1,73 m2, primjenu treba početi s dozom od 100 mg dvaput dnevno u bolesnika s Gaucherovom bolesti tipa 1, te dozom od 200 mg dvaput dnevno (prilagođeno površini tijela u bolesnika mlađih od 12 godina) u bolesnika s Niemann-Pickovom bolesti tipa C.
Due to limited experience, Yargesa should be used with caution in patients with renal or hepatic impairment. 
Zbog ograničenog iskustva, kod bolesnika s poremećajem funkcije bubrega ili jetre, lijek Yargesa treba koristiti oprezno.
Therapy should be directed by physicians who are knowledgeable in the management of Gaucher disease or Niemann-Pick type C disease, as appropriate. 
Liječenje trebaju voditi liječnici s odgovarajućim iskustvom u liječenju Gaucherove bolesti ili NiemannPickove bolesti tipa C.
In patients with an adjusted creatinine clearance of 30-50 ml/min/1.73 m2, administration should commence at a dose of 100 mg once daily in patients with type 1 Gaucher disease and at a dose of 100 mg twice daily (adjusted for body surface area in patients below the age of 12) in patients with Niemann-Pick type C disease. 
Kod bolesnika s prilagođenim klirensom kreatinina od 30-50 ml/min/1,73 m2, primjenu treba početi s dozom od 100 mg jednom dnevno u bolesnika s Gaucherovom bolesti tipa 1, te dozom od 100 mg dvaput dnevno (prilagođeno površini tijela u bolesnika mlađih od 12 godina) u bolesnika s Niemann-Pickovom bolesti tipa C.
How to take Yargesa 
Kako uzimati lijek Yargesa
The recommended dose for the treatment of adult patients with Niemann-Pick type C disease is 200 mg three times a day. 
Preporučena doza za liječenje odraslih bolesnika s Niemann-Pickovom bolesti tipa C je 200 mg triput dnevno.
Male patients should use reliable birth control methods during their treatment with Yargesa and for 3 months after finishing treatment. 
Muški bolesnici trebaju primjenjivati pouzdane metode kontracepcije tijekom liječenja lijekom Yargesa, te još 3 mjeseca nakon završetka liječenja.
Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. 
Yargesa je indicirana za peroralno liječenje odraslih bolesnika s blagom do umjerenom Gaucherovom bolesti tipa
There were no events of bone crisis, avascular necrosis or fracture during the treatment period. 
Tijekom razdoblja liječenja nije bilo koštanih kriza, avaskularnih nekroza niti lomova.
A total daily dose of 300 mg miglustat administered in three divided doses was used in the above two studies. 
U gornja dva ispitivanja primijenjena je ukupna dnevna doza miglustata od 300 mg u tri pojedinačne doze.
Monitoring of platelet counts is recommended in these patients. 
U tih se bolesnika preporučuje praćenje broja trombocita.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti Prilog I: Sažetak opisa svojstava lijeka, dio 4.2)
Dosage in type 1 Gaucher disease 
Doziranje kod Gaucherove bolesti tipa 1 Odrasli
How to store Yargesa 
Kako čuvati lijek Yargesa
The hard capsule consists of an opaque white cap and body with “708” printed in black on the body. 
Tvrda kapsula sastoji se od neprozirne bijele kapice i tijela na kojem je otisnuto „708” crnom bojom Veličina kapsule: 4 (14,3 mm x 5,3 mm)
Hepatic Impairment Yargesa has not been evaluated in patients with hepatic impairment. 
Lijek Yargesa nije procjenjivan kod bolesnika s oštećenjem funkcije jetre.